Abyssinia is altering the world's understanding of Alzheimer's Disease from diagnostic assays with the potential for early diagnosis to treatment approaches addressing novel disease causes. Abyssinia's lead candidate ABY-71A1 is a IgG1 mAb with a high specificity for toxic soluble amyloid oligomers,... Read more
This company has no teams yet